Despite an explosion in understanding of the disease process, the rates of patients with autosomal dominant polycystic kidney disease starting renal replacement therapy show no signs of slowing. Indeed, rates among people aged ≥70 years have increased, reflecting a greater propensity to offer renal replacement therapy to this age group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. http://dx.doi.org/10.1038/ki.2014.120.
Shaw, C., Simms, R. J., Pitcher, D. & Sandford, R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfu087.
Stewart, J. H., McCredie, M. R., Williams, S. M. & McDonald, S. P. Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology 9, 238–246 (2004).
Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037–2047 (1995).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Patch, C., Charlton, J., Roderick, P. J. & Gulliford, M. C. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am. J. Kid. Dis. 57, 856–862 (2011).
Grantham, J. J. Therapy for polycystic kidney disease? It's water, stupid! J. Am. Soc. Nephrol. 19, 1–7 (2008).
Higashihara, E. et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfu093.
Neumann, H. P. et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol. Dial. Transplant. 28, 1472–1487 (2013).
Orskov, B., Sorensen, V. R., Feldt-Rasmussen, B. & Strandgaard, S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol. Dial. Transplant. 27, 1607–1613 (2012).
Acknowledgements
The ANZDATA Registry is funded by the Australian Organ and Tissue Donation and Transplantation Authority, the New Zealand Ministry of Health and Kidney Health Australia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.M. and G.R. are site-investigators in an ongoing clinical trial of tolvaptan for ADPKD (Otsuka Pharmaceutical Ltd)
Rights and permissions
About this article
Cite this article
McDonald, S., Rangan, G. Progression of polycystic kidney disease—a lack of progress?. Nat Rev Nephrol 10, 489–491 (2014). https://doi.org/10.1038/nrneph.2014.138
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.138
